Lundbeckfonden Emerge News

Copenhagen, Denmark – August 29th, 2017: Danish-based Dermtreat today announced the GMP (Good Manufacturing Practices) approval for the production of its novel Rivelin® patch – a breakthrough therapy in treating mucosal diseases. Dermtreat has developed the Rivelin® patch – a breakthrough therapy for the treatment of mucosal diseases. Rivelin® is designed to deliver a pharmaceutical...
Copenhagen, Denmark – May 8, 2017: Danish-based Dermtreat today announced the successful closure of a USD 17.7 mill. Series A financing led by the US-based leading venture capital firm, Sofinnova, with the leading Nordic venture capital firms Novo Seeds and Lundbeckfonden Emerge in the syndicate. Existing shareholders are also participating. Dermtreat has developed the Rivelin®...
NMD Pharma develops new treatments, improving the signaling of the nerves to the muscles, to patients suffering from orphan motor neuron diseases including Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA). The company has identified a novel disease target and developed new small molecule drug-like compounds effectively increasing neuromuscular transmission. In models...
 IO Biotech today announced the successful completion of a ?11 million Series A financing round. Participants were new investor Lundbeckfonden as well as existing investor Novo A/S.
Lundbeck Foundation is investing a further DKK 15 million in Aarhus-based Insusense Therapeutics, a biotech company which develops new drugs for the treatment of type 2 diabetes and obesity.
Lundbeck Foundation has decided to invest DKK 300 million in Danish biotech companies over the next four years. The funds will be invested by Lundbeckfond Emerge with the aim of generating a portfolio of five active companies over the course of a couple of years.